Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

All of this means Lilly investors shouldn't panic. Even in the "worst case," Lilly's weight loss drugs have driven major revenue growth, and this is likely to continue -- whether compounders halt ...

Studies show that people with obesity are more likely to find that ill health affects their productivity and attendance at work.

Support for people living with obesity is “insufficient”, experts have said after a new report revealed that some patients are being asked to wait for up to five years for specialist support. Some ...